Differentiated Thyroid Cancer
📧 Sign up to get email alerts when something new happens for Differentiated Thyroid Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-01-12Clinical Trial Update: A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer [Phase 1, Phase 2]
Phase I/II trial of MLN0128 in metastatic anaplastic thyroid cancer and poorly differentiated or radioiodine-refractory differentiated thyro…
-
CLINICAL_TRIALS trial_result · 2023-12-19Clinical Trial Update: High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial comparing high dose versus low dose Iodine-131 with or without rhTSH in differentiated thyroid cancer; current status is unkno…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer [Phase 3]
Phase 3 clinical trial update evaluating the efficacy and safety of recombinant human TSH (rhTSH) as adjuvant radioiodine ablation therapy i…
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer. [Phase 2]
Phase 2 trial update evaluating safety and effectiveness of rhTSH in radioiodine treatment for differentiated thyroid cancer.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy [Phase 3]
Phase 3 study comparing cabozantinib to placebo in radioiodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2023-05-17Clinical Trial Update: Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? [Phase 3]
A Phase 3 clinical trial evaluating whether radioiodine ablation is needed for low-risk differentiated thyroid cancer patients.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer [Phase 3]
Phase 3 trial update evaluating apatinib for radioactive iodine-refractory differentiated thyroid cancer.
-
FDA approval · 2022-09-16FDA Approved: LEVOTHYROXINE SODIUM — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for Accord Healthcare's levothyroxine sodium, a generic thyroid hormone replacement product.
-
CLINICAL_TRIALS trial_result · 2022-07-20Clinical Trial Update: Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases [Phase 4]
Phase 4 trial update on the efficacy of Strontium-89 (Sr-89) for differentiated thyroid cancer with bone metastases.
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry [Phase 2]
Phase 2 trial update on optimizing therapy for metastatic differentiated thyroid cancer using 124I PET dosimetry.
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas [Phase 2]
Phase 2 trial evaluating lenvatinib plus denosumab for predominantly bone metastatic radioiodine-refractory differentiated thyroid carcinoma…
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: Anlotinib or Penpulimab in Combination With RAI for DTC [Phase 2]
Phase 2 clinical trial exploring anlotinib or penpulimab in combination with radioactive iodine for differentiated thyroid cancer.
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China [Phase 3]
Phase 3 trial assessing lenvatinib (E7080) in radioiodine-refractory differentiated thyroid cancer conducted in China has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: Study of Apatinib in Patients With Differentiated Thyroid Cancer [Phase 2]
Phase 2 clinical trial update of apatinib in differentiated thyroid cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer [Phase 3]
Phase 3 study of donafenib in radioiodine-refractory differentiated thyroid cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone [Phase 2]
Phase 2 clinical trial evaluating the combination of everolimus and sorafenib in differentiated thyroid cancer patients who progressed on so…
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis [NA]
Clinical trial update on 99Tc-MDP in postmenopausal women with differentiated thyroid cancer and osteoporosis; trial completed with results …
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting [Phase 2]
Phase II trial investigating cabozantinib as first-line treatment for radioiodine-refractory differentiated thyroid carcinoma (DTC).
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer [Phase 2]
Phase 2 adaptive TKI therapy trial in thyroid cancer was terminated; results posted previously.
-
CLINICAL_TRIALS trial_result · 2021-01-11Clinical Trial Update: A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile [Phase 2]
Phase 2 trial evaluating whether starting lenvatinib at 18 mg daily offers comparable efficacy to 24 mg with a better safety profile in iodi…
-
CLINICAL_TRIALS trial_result · 2020-09-17Clinical Trial Update: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma [Phase 1, Phase 2]
Phase 1/2 trial of lenvatinib in pediatric/adolescent and young adult patients with refractory or relapsed solid malignancies and osteosarco…
-
CLINICAL_TRIALS trial_result · 2020-07-31Clinical Trial Update: Nintedanib(BIBF1120) in Thyroid Cancer [Phase 2]
Phase 2 trial of nintedanib (BIBF1120) in thyroid cancer (medullary and differentiated thyroid cancer) has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-27Clinical Trial Update: Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers [Phase 2]
Phase 2 trial evaluating a neoadjuvant regimen for radioactive iodine treatment in metastatic and advanced differentiated thyroid cancers; s…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer [Phase 2]
Phase II trial of Sorafenib (Nexavar) in advanced thyroid cancers completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology [Phase 2]
Phase 2 trial evaluating safety and efficacy of oral lenvatinib in medullary and iodine-131 refractory, unresectable differentiated thyroid …